Relacorilant, a Selective Glucocorticoid Receptor Modulator in Development for the Treatment of Patients With Cushing Syndrome, Does not Cause Prolongation of the Cardiac QT Interval

To assess the effect of relacorilant, a selective glucocorticoid receptor modulator under investigation for the treatment of patients with endogenous hypercortisolism (Cushing syndrome [CS]), on the heart rate–corrected QT interval (QTc). Three clinical studies of relacorilant were included: (1) a f...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Endocrine practice 2024-01, Vol.30 (1), p.11-18
Hauptverfasser:	Donegan, Diane M., Pivonello, Rosario, Stigliano, Antonio, Lardo, Pina, Kearney, Tara, Mezősi, Emese, Ghigo, Ezio, Giordano, Roberta, Mariash, Cary N., Feelders, Richard A., Donaldson, Kirsteen, Darpo, Borje, Xue, Hongqi, Custodio, Joseph M., Hand, Austin L., Moraitis, Andreas G.
Format:	Artikel
Sprache:	eng
Schlagworte:	cardiac safety Clinical Trials, Phase I as Topic Clinical Trials, Phase II as Topic Cross-Over Studies Cushing syndrome Cushing Syndrome - drug therapy Dose-Response Relationship, Drug Double-Blind Method Electrocardiography Healthy Volunteers Humans Long QT Syndrome - chemically induced Long QT Syndrome - drug therapy Moxifloxacin QT interval prolongation Randomized Controlled Trials as Topic Receptors, Glucocorticoid relacorilant selective glucocorticoid receptor modulator
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!